Unknown

Dataset Information

0

Peptide and peptide-based inhibitors of SARS-CoV-2 entry.

ABSTRACT: To date, no effective vaccines or therapies are available against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative pandemic agent of the coronavirus disease 2019 (COVID-19). Due to their safety, efficacy and specificity, peptide inhibitors hold great promise for the treatment of newly emerging viral pathogens. Based on the known structures of viral proteins and their cellular targets, antiviral peptides can be rationally designed and optimized. The resulting peptides may be highly specific for their respective targets and particular viral pathogens or exert broad antiviral activity. Here, we summarize the current status of peptides inhibiting SARS-CoV-2 entry and outline the strategies used to design peptides targeting the ACE2 receptor or the viral spike protein and its activating proteases furin, transmembrane serine protease 2 (TMPRSS2), or cathepsin L. In addition, we present approaches used against related viruses such as SARS-CoV-1 that might be implemented for inhibition of SARS-CoV-2 infection.

SUBMITTER: Schutz D 

PROVIDER: S-EPMC7665879 | biostudies-literature | 2020 Dec

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Peptide and peptide-based inhibitors of SARS-CoV-2 entry.

Schütz Desiree D   Ruiz-Blanco Yasser B YB   Münch Jan J   Kirchhoff Frank F   Sanchez-Garcia Elsa E   Müller Janis A JA  

Advanced drug delivery reviews 20201113

To date, no effective vaccines or therapies are available against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative pandemic agent of the coronavirus disease 2019 (COVID-19). Due to their safety, efficacy and specificity, peptide inhibitors hold great promise for the treatment of newly emerging viral pathogens. Based on the known structures of viral proteins and their cellular targets, antiviral peptides can be rationally designed and optimized. The resulting peptid  ...[more]

Similar Datasets

Unknown Peptide-Based Inhibitors for SARS-CoV-2 and SARS-CoV.
| S-EPMC8420164 | biostudies-literature
Unknown Computational Design of ACE2-Based Peptide Inhibitors of SARS-CoV-2.
| S-EPMC7163933 | biostudies-literature
Unknown Discovery of Small Molecule Entry Inhibitors Targeting the Fusion Peptide of SARS-CoV-2 Spike Protein.
| S-EPMC8353886 | biostudies-literature
Unknown Peptide-based pan-CoV fusion inhibitors maintain high potency against SARS-CoV-2 Omicron variant.
| S-EPMC8793821 | biostudies-literature
Unknown Structure-based design, synthesis, and biological evaluation of peptidomimetic SARS-CoV 3CLpro inhibitors.
| S-EPMC2112940 | biostudies-other
Unknown Inhibitors of SARS-CoV-2 Entry: Current and Future Opportunities.
| S-EPMC7315836 | biostudies-literature
Unknown Computational designing of a peptide that potentially blocks the entry of SARS-CoV, SARS-CoV-2 and MERS-CoV.
| S-EPMC8130920 | biostudies-literature
Unknown Development of cell-based pseudovirus entry assay to identify potential viral entry inhibitors and neutralizing antibodies against SARS-CoV-2.
| S-EPMC7366953 | biostudies-literature
Unknown Pharmacoinformatics-based identification of transmembrane protease serine-2 inhibitors from Morus Alba as SARS-CoV-2 cell entry inhibitors.
| S-EPMC8009078 | biostudies-literature
Unknown Identification of SARS-CoV-2 entry inhibitors among already approved drugs.
| S-EPMC7594953 | biostudies-literature